ClinicalTrials.gg
CompletedNCT00122382Updated Nov 16, 2010Results posted

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

A Phase 3 interventional study of Abatacept and placebo in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 89 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-16.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,052
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
5th of 63
1,052 · median 119
Started
2005
with 3 others
Phase 3
26 of 63
2 open now
Registered
7th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 5th largest by enrollment, is one of 4 that started in 2005, is one of 26 in phase 3, and was the 7th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • abatacept, methotrexate, erosive RA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of rheumatoid arthritis (RA) \<=2 years; MTX naive or \<=10 mg/wk for \<=3 weeks. No dose within 3 months prior to .
  • C-Reactive Protein (CRP) >= 4.5 mg/L (after amendment)
  • Rheumatoid factor or anti-cyclic citrullinated peptide antibody (anti-CCP) positive
  • Tender joints >=12 and swollen joints >=10

Exclusion criteria

Exclusion Criteria:

  • Women and men who are not willing to use
  • Diagnosed with other rheumatic disease
  • History of cancer within 5 years
  • Active tuberculosis
  • Treatment with another investigation drug within 28 days
  • Active bacterial or viral infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,052 participants (actual)

Study arms

  • Active comparator
    ABA + MTX

    abatacept 10 mg/kg intravenous (IV) + methotrexate

    Drug: Abatacept · Drug: methotrexate

  • Active comparator
    Placebo (PLA) + MTX

    placebo IV + methotrexate

    Drug: Abatacept · Drug: placebo · Drug: methotrexate

Interventions

  • abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months

  • Drugplacebo

    placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months

  • Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24

06

What researchers measure

Primary outcomes

  1. Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12

    Number of participants who achieved remission at Month 12 of treatment, as defined by a Disease Activity Score (DAS) 28-CRP score of \<2.6. DAS 28-CRP is a continuous measure, a composite of 4 variables: number of tender joints out of 28 joints, number of swollen joints out of 28 joints, CRP (in mg/L), and subject assessment of disease activity measure on a Visual Analogue Scale (VAS) of 100 millimeters (mm). The DAS28 scale=0 (best) to 10 (worst), indicating the current activity of the rheumatoid arthritis. A DAS28 \>5.1 = high disease activity; \<=3.2 = low disease activity; \<2.6 = remission.

    Time frame: Month 12

  2. Mean Change From Baseline in Radiographic Total Score to Month 12

    To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and joint space narrowing (JSN). The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.

    Time frame: Baseline, Month 12

  3. Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to AEs During the Open-Label Period

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

    Time frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.

  4. Number of Participants With Serious Adverse Events Reported During the Open-Label Period

    SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

    Time frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.

  5. Number of Participants With SAEs With an Outcome of Death During the Open-label Period

    Any untoward medical occurrence (SAE) that resulted in death

    Time frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.

  6. Incidence Rates of Autoimmune Disorders in ABA-Treated Participants

    The incidence rates of autoimmune disorders are defined as the (number of patients experiencing the event/exposure within the period)\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.

    Time frame: Double Blind Period (+56 days post last dose in double-blind period or start of open-label period, whichever came first). Open-label period (56 days post last dose in the open-label period or start of maintenance sub-study, whichever came first).

  7. Incidence Rates of Infections and Infestations of Adverse Events in ABA-Treated Participants

    The incidence rates of infections and infestations are defined as the (number of patients experiencing the event /exposure within the period)\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.

    Time frame: Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first).

  8. Incidence Rates of Malignant Neoplasm Adverse Events in ABA-Treated Participants

    The incidence rates of malignant neoplasms are defined as the (number of patients experiencing the event /exposure within the period)\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.

    Time frame: Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first).

  9. Number of Participants With a Serious Acute-Infusional AE of Anaphylactic Shock During Open-Label Period

    There were 107 Prespecified, acute-infusional SAEs (occurring within 1 hour after the start of study drug infusion) pre-specified in the protocol; anaphylactic shock was the only one occuring in this study.

    Time frame: Open-Label Period (Month 12 to Month 24)

  10. Number of Participants With Select Blood Chemistry Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period

    Number of subjects with high liver function and kinedy tests: alkaline phosphatase (ALP) \>2x upper limit of normal (ULN) or if pretreatment (PRE-RX) \>ULN then \>3x PRE-RX; aspartate aminotransferase (AST) \>3x ULN or if PRE-RX \>ULN then \>4x PRE-RX; alanine aminotransferase (ALT) \>3x ULN or if PRE-RX \>ULN then \>4x PRE-RX; g-glutamyl transferase (GGT)\>2x ULN or if PRE-RX \>ULN then \>3x PRE-RX; total bilirubin \>2x ULN or if PRE-RX \>ULN then \>4x PRE-RX; blood urea nitrogen \>2x PRE-RX; creatinine \>1.5x PRE-RX.

    Time frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.

  11. Number of Participants With Hematology Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period

    Marked abnormalities in hemoglobin \>3 g/dL decrease from PRE-RX; hematocrit \<0.75x PRE-RX; erythrocytes \<0.75x PRE-RX; platelet count \<0.67x lower limit of normal (LLN) or \>1.5x ULN or if PRE-RX \<LLN then \<0.5x PRE-RX and \<100,000/mm3; leukocytes \<0.75x LLN or \>1.25x ULN or if PRE-RX \<LLN then \<0.8x PRE-RX or \>ULN if PRE-RX \>ULN then \>1.2x PRE-RX or \<LLN; neutrophils if value \<1.00 x10\^3 c/uL; lymphocytes if value \<.750 x10\^3 c/uL or if value \>7.50 x10\^3 c/uL; monocytes if value \>2000/MM3; basophils if value \>400/mm3; eosinophils if value \>.750 x10\^3 c/uL

    Time frame: Continuously from start of open-label period up to 56 days post the last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.

Secondary outcomes

  1. Number of Participants With American College of Rheumatology (ACR) 50 Response at Month 12

    ACR 50 response was defined as a 50% improvement from baseline to Month 12 in tender and swollen joint counts and 50% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function), and 1 acute phase reactant value \[ie, CRP\].

    Time frame: Month 12

  2. Number of Participants With Major Clinical Response (MCR) at Month 12

    MCR was defined as 6 months of consecutive ACR 70 response at Month 12. ACR 70, the American College of Rheumatology (ACR) definition of 70% improvement was based on a 70% improvement (compared to baseline values) in tender and swollen joint counts and 70% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function, and 1 acute phase reactant value \[ie, CRP\]).

    Time frame: Month 12

  3. Adjusted Mean Change From Baseline in DAS-28-CRP Score to Month 12

    DAS 28-CRP is a continuous variable that is a composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, CRP in milligrams/Liter (mg/L), and subject assessment of disease activity measure on a Visual Analogue Scale (VAS) of 100 millimeters (mm). The DAS28 scale=0 to 10, indicating the current activity of the rheumatoid arthritis. A DAS28 \>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission. Change from Baseline=Post-baseline - Baseline value; Adjusted for baseline value.

    Time frame: Baseline, Month 12

  4. Number of Participants With Health Assessment Questionnaire (HAQ) Response at Month 12

    Physical function was evaluated using the HAQ-disability index (HAQ-DI), a questionnaire with 20 questions assessing function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; 3 = unable to do. The 8 category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). Higher scores indicate greater dysfunction. HAQ response=improvement of at least 0.3 units from baseline.

    Time frame: Month 12

  5. Adjusted Mean Change in Short Form 36 (SF-36) From Baseline to Month 12

    The SF-36 covers 8 health dimensions: 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from 0 to 100, with a higher score indicating better quality of life. Two summary scores (physical and mental component summaries) were produced taking a weighted linear combination of the 8 individual subscales. Change from Baseline=Post-baseline - Baseline value; adjusted for baseline value.

    Time frame: Baseline, Month 12

  6. Mean Change From Baseline in Radiographic Erosion and Joint Space Narrowing (JSN) Scores to Month 12

    To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The erosion score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). The joint space narrowing score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). Higher scores indicated more damage. Change from baseline = Post-baseline - Baseline value

    Time frame: Baseline, Month 12

  7. Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses in the Double-blind Period as Analyzed by Enzyme-linked-immunosorbent Serologic Assay (ELISA)

    Serum samples were analyzed by ELISA to detect antibodies against the whole molecule (both CTLA4 and Ig \[anti-abatacept antibody\]) or solely to CTLA4 (anti-CTLA4-T antibody). Reported as titer, the reciprocal of the sample dilution which yielded a signal equivalent to the statistically set cut point for the assay. For the anti-abatacept assay, minimum required dilution is 400-fold, therefore seronegative samples are those \< lowest reportable titer (\<400). For the anti-CTLA4-T assay, minimum required dilution is 25-fold, therefore seronegative samples are those \< lowest reportable titer (\<25).

    Time frame: includes data up to approximately 85 days past the last dose of the double-blind period or start of the open-label period, whichever occurred first.

  8. Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses During the Open-Label Period (From Month 12 to Month 24) as Analyzed by ELISA

    Serum samples were analyzed by ELISA to detect antibodies against the whole molecule (both CTLA4 and Ig \[anti-abatacept antibody\]) or solely to CTLA4 (anti-CTLA4-T antibody). Reported as titer, the reciprocal of the sample dilution which yielded a signal equivalent to the statistically set cut point for the assay. For the anti-abatacept assay, minimum required dilution is 400-fold, therefore seronegative samples are those \< lowest reportable titer (\<400). For the anti-CTLA4-T assay, minimum required dilution is 25-fold, therefore seronegative samples are those \< lowest reportable titer (\<25).

    Time frame: Includes open-label data up to approximately 85 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.

  9. Number of Participants With Health Assessment Questionnaire (HAQ) Response at Month 24

    Physical function was evaluated using the HAQ-disability index (HAQ-DI), a questionnaire with 20 questions assessing function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; 3 = unable to do. The 8 category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). Higher scores indicate greater dysfunction. HAQ response=improvement of at least 0.3 units from baseline.

    Time frame: Baseline, Month 24

  10. Mean Change From Baseline in Radiographic Total, Erosion and JSN Scores to Month 24

    To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. Change from baseline = Postbaseline - baseline value.

    Time frame: Baseline, Month 24

  11. Number of Participants Without Radiographic Progression (as Measured by in Erosion Scores, JSN Scores, and Total Scores) From Baseline at Month 24

    Participants with no radiographic progression (defined as change in score \<=0 or \<=0.5), from baseline to Month 24. To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.

    Time frame: Baseline, Month 24

  12. Number of Participants Without Radiographic Progression (as Measured by in Erosion Scores, JSN Scores, and Total Scores) at Month 24 in Participants Without Progression at Month 12

    Participants with no radiographic progression ((defined as change in score \<=0 or \<=0.5), sustained from Month 12 and Month 24. To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.

    Time frame: Month 12, Month 24

  13. Mean Difference Observed in Change From Baseline to Month 12 and Between Month 12 and Month 24 in Radiographic Scores (Total Score)

    Mean difference observed in change from baseline to Month 12 and between Month 12 and Month 24 in radiographic scores (Total Score). To assess joint damage, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.

    Time frame: Baseline, Month 12, Month 24

  14. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Reported During the Double-blind Period

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

    Time frame: Includes data up to 56 days post the last dose in the double-blind period or start of the open-label period, whichever occurred first.

  15. Number of Participants With Laboratory Values Meeting the Marked Abnormality Criteria During the Double-blind Period

    Number of participants with laboratory values (hematology, liver and kidney functions, electrolytes, glucose tests, protein tests, metabolite tests, and urine chemistry tests) considered markedly abnormal according to prespecified protocol criteria

    Time frame: Includes data up to 56 days post the last dose in the double-blind period or start of the open-label period, whichever occurred first.

07

Results

Posted Jul 13, 2010

Participant flow

Double-Blind Study
Participant flow — Double-Blind Study
MilestoneAbatacept (ABA) + Methotrexate (MTX) (Double-Blind)Placebo (PLA) + Methotrexate (MTX) (Double-Blind)ABA + MTX (Open-Label)
Started2562550
Treated2562530
Completed2322270
Not completed24280
Withdrew: Adverse event9110
Withdrew: Death220
Withdrew: Lack of efficacy080
Withdrew: Lost to follow-up210
Withdrew: Pregnancy200
Withdrew: Subject no longer meets study criteria100
Withdrew: Withdrawal of consent730
Withdrew: Protocol violation100
Withdrew: Methotrexate discontinued010
Withdrew: Randomized but not treated020
Open-Label Study
Participant flow — Open-Label Study
MilestoneAbatacept (ABA) + Methotrexate (MTX) (Double-Blind)Placebo (PLA) + Methotrexate (MTX) (Double-Blind)ABA + MTX (Open-Label)
Started00459
Completed00433
Not completed0026
Withdrew: Adverse event0011
Withdrew: Death002
Withdrew: Lack of efficacy003
Withdrew: Lost to follow-up003
Withdrew: Pregnancy002
Withdrew: Poor/non-compliance001
Withdrew: Withdrawal of consent004

Outcome measures

SecondaryNumber of Participants With American College of Rheumatology (ACR) 50 Response at Month 12

ACR 50 response was defined as a 50% improvement from baseline to Month 12 in tender and swollen joint counts and 50% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function), and 1 acute phase reactant value \[ie, CRP\].

Time frame:
Month 12
Reported as:
Number · participants
Number of Participants With American College of Rheumatology (ACR) 50 Response at Month 12
participantsABA + MTX (Double-Blind)PLA + MTX (Double-Blind)
Number of Participants With American College of Rheumatology (ACR) 50 Response at Month 12147107
Statistical analysis
  • ABA + MTX (Double-Blind) vs PLA + MTX (Double-Blind) · Chi-squared, Continuity-Corrected · p = <0.001 (p-value of \<0.05: probability for testing the difference between ABA and PLA.) · Estimated difference between aba and pla: 15.1 · 95% CI 6.0 to 24.2
SecondaryNumber of Participants With Major Clinical Response (MCR) at Month 12

MCR was defined as 6 months of consecutive ACR 70 response at Month 12. ACR 70, the American College of Rheumatology (ACR) definition of 70% improvement was based on a 70% improvement (compared to baseline values) in tender and swollen joint counts and 70% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function, and 1 acute phase reactant value \[ie, CRP\]).

Time frame:
Month 12
Reported as:
Number · participants
Number of Participants With Major Clinical Response (MCR) at Month 12
participantsABA + MTX (Double-Blind)PLA + MTX (Double-Blind)
Number of Participants With Major Clinical Response (MCR) at Month 127030
Statistical analysis
  • ABA + MTX (Double-Blind) vs PLA + MTX (Double-Blind) · Chi-squared, Continuity-Corrected · p = <0.001 (p-value of \<0.05: probability for testing the difference between ABA and PLA.) · Estimated difference between aba and pla: 15.5 · 95% CI 8.2 to 22.8
SecondaryAdjusted Mean Change From Baseline in DAS-28-CRP Score to Month 12

DAS 28-CRP is a continuous variable that is a composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, CRP in milligrams/Liter (mg/L), and subject assessment of disease activity measure on a Visual Analogue Scale (VAS) of 100 millimeters (mm). The DAS28 scale=0 to 10, indicating the current activity of the rheumatoid arthritis. A DAS28 \>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission. Change from Baseline=Post-baseline - Baseline value; Adjusted for baseline value.

Time frame:
Baseline, Month 12
Reported as:
Mean · units in a scale
Adjusted Mean Change From Baseline in DAS-28-CRP Score to Month 12
units in a scaleABA + MTX (Double-Blind)PLA + MTX (Double-Blind)
Adjusted Mean Change From Baseline in DAS-28-CRP Score to Month 12-3.22 ± 0.09-2.49 ± 0.09
Statistical analysis
  • ABA + MTX (Double-Blind) vs PLA + MTX (Double-Blind) · ANCOVA · p = <0.001 (p-value of \<0.05: probability for testing the difference between ABA and PLA.) · Estimate of/adjusted difference: -0.73 · 95% CI -0.98 to -0.48Adjustment based on ANCOVA model with treatment as factor and baseline value as covariate.
SecondaryNumber of Participants With Health Assessment Questionnaire (HAQ) Response at Month 12

Physical function was evaluated using the HAQ-disability index (HAQ-DI), a questionnaire with 20 questions assessing function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; 3 = unable to do. The 8 category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). Higher scores indicate greater dysfunction. HAQ response=improvement of at least 0.3 units from baseline.

Time frame:
Month 12
Reported as:
Number · participants
Number of Participants With Health Assessment Questionnaire (HAQ) Response at Month 12
participantsABA + MTX (Double-Blind)PLA + MTX (Double-Blind)
Number of Participants With Health Assessment Questionnaire (HAQ) Response at Month 12184157
Statistical analysis
  • ABA + MTX (Double-Blind) vs PLA + MTX (Double-Blind) · Chi-squared, Continuity-Corrected · p = 0.024 (p-value of \<0.05: probability for testing the difference between ABA and PLA.) · Estimated difference between aba and pla: 9.8 · 95% CI 1.3 to 18.4
SecondaryAdjusted Mean Change in Short Form 36 (SF-36) From Baseline to Month 12

The SF-36 covers 8 health dimensions: 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from 0 to 100, with a higher score indicating better quality of life. Two summary scores (physical and mental component summaries) were produced taking a weighted linear combination of the 8 individual subscales. Change from Baseline=Post-baseline - Baseline value; adjusted for baseline value.

Time frame:
Baseline, Month 12
Reported as:
Mean · units on a scale
Adjusted Mean Change in Short Form 36 (SF-36) From Baseline to Month 12
units on a scaleABA + MTX (Double-Blind)PLA + MTX (Double-Blind)
Physical Component Summary (PCS) Score11.68 ± 0.629.18 ± 0.63
Mental Component Summary (MCS) Score8.15 ± 0.646.34 ± 0.64
Statistical analysis
  • ABA + MTX (Double-Blind) vs PLA + MTX (Double-Blind) · ANCOVA · p = 0.005 (p-value of \<0.05: probability for testing the difference between ABA and PLA.) · Estimate of/adjusted difference: 2.50 · 95% CI 0.77 to 4.23Adjustment based on ANCOVA model with treatment as factor and baseline value as covariate.
  • ABA + MTX (Double-Blind) vs PLA + MTX (Double-Blind) · ANCOVA · p = 0.046 (p-value of \<0.05: probability for testing the difference between ABA and PLA.) · Estimate of/adjusted difference: 1.81 · 95% CI 0.03 to 3.60Adjustment based on ANCOVA model with treatment as factor and baseline value as covariate.
SecondaryMean Change From Baseline in Radiographic Erosion and Joint Space Narrowing (JSN) Scores to Month 12

To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The erosion score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). The joint space narrowing score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). Higher scores indicated more damage. Change from baseline = Post-baseline - Baseline value

Time frame:
Baseline, Month 12
Reported as:
Mean · units on a scale
Mean Change From Baseline in Radiographic Erosion and Joint Space Narrowing (JSN) Scores to Month 12
units on a scaleABA + MTX (Double-Blind)PLA + MTX (Double-Blind)
Baseline Mean Erosion Score5.48 ± 6.154.81 ± 5.46
Mean Change from Baseline in Erosion Score0.50 ± 1.390.89 ± 2.24
Baseline Mean JSN Score2.03 ± 3.991.86 ± 3.95
Mean Change from Baseline in JSN Score0.13 ± 0.530.17 ± 0.54
Statistical analysis
  • ABA + MTX (Double-Blind) vs PLA + MTX (Double-Blind) · Nonparametric ANCOVA · p = 0.033 (P-value of \<0.05: probability for comparison of change in radiographic scores between abatacept and placebo.)
  • ABA + MTX (Double-Blind) vs PLA + MTX (Double-Blind) · Nonparametric ANCOVA · p = 0.353 (P-value of \<0.05: probability for comparison of change in radiographic scores between abatacept and placebo.)
SecondaryNumber of Participants With Anti-abatacept or Anti-CTLA4-T Responses in the Double-blind Period as Analyzed by Enzyme-linked-immunosorbent Serologic Assay (ELISA)

Serum samples were analyzed by ELISA to detect antibodies against the whole molecule (both CTLA4 and Ig \[anti-abatacept antibody\]) or solely to CTLA4 (anti-CTLA4-T antibody). Reported as titer, the reciprocal of the sample dilution which yielded a signal equivalent to the statistically set cut point for the assay. For the anti-abatacept assay, minimum required dilution is 400-fold, therefore seronegative samples are those \< lowest reportable titer (\<400). For the anti-CTLA4-T assay, minimum required dilution is 25-fold, therefore seronegative samples are those \< lowest reportable titer (\<25).

Time frame:
includes data up to approximately 85 days past the last dose of the double-blind period or start of the open-label period, whichever occurred first.
Reported as:
Number · Participants
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses in the Double-blind Period as Analyzed by Enzyme-linked-immunosorbent Serologic Assay (ELISA)
ParticipantsABA+ MTX On-treatmentABA + MTX Post-discontinuation
Anti-abatacept Responses30
Anti-CTLA4-T Responses11
PrimaryNumber of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12

Number of participants who achieved remission at Month 12 of treatment, as defined by a Disease Activity Score (DAS) 28-CRP score of \<2.6. DAS 28-CRP is a continuous measure, a composite of 4 variables: number of tender joints out of 28 joints, number of swollen joints out of 28 joints, CRP (in mg/L), and subject assessment of disease activity measure on a Visual Analogue Scale (VAS) of 100 millimeters (mm). The DAS28 scale=0 (best) to 10 (worst), indicating the current activity of the rheumatoid arthritis. A DAS28 \>5.1 = high disease activity; \<=3.2 = low disease activity; \<2.6 = remission.

Time frame:
Month 12
Reported as:
Number · participants
Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12
participantsABA + MTX (Double-Blind)PLA + MTX (Double-Blind)
Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 1210659
Statistical analysis
  • ABA + MTX (Double-Blind) vs PLA + MTX (Double-Blind) · Chi-squared, Continuity-Corrected · p = <0.001 (Total score was tested only if there was statistical significance in remission rate. For each test, the nominal type I error rate is set at 5%; this sequential testing procedure preserves the overall type I error rate at 5%.) · Estimated difference between aba and pla: 18.1 · 95% CI 9.6 to 26.6
PrimaryMean Change From Baseline in Radiographic Total Score to Month 12

To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and joint space narrowing (JSN). The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.

Time frame:
Baseline, Month 12
Reported as:
Mean · units on a scale
Mean Change From Baseline in Radiographic Total Score to Month 12
units on a scaleABA + MTX (Double-Blind)PLA + MTX (Double-Blind)
Baseline Mean7.50 ± 9.526.67 ± 8.71
Mean Change from Baseline0.63 ± 1.741.06 ± 2.45
Statistical analysis
  • ABA + MTX (Double-Blind) vs PLA + MTX (Double-Blind) · non-parametric ANCOVA · p = <0.040 (Total score was tested only if there was statistical significance in remission rate. For each test, the nominal type I error rate is set at 5%; this sequential testing procedure preserves the overall type I error rate at 5%.)
PrimaryNumber of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to AEs During the Open-Label Period

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

Time frame:
Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
Reported as:
Number · participants
Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to AEs During the Open-Label Period
participantsABA + MTX (Open-Label)
AEs345
Related AEs128
SAEs29
Related SAEs10
Discontinuations due to AEs11
Discontinuations due to SAEs4
Deaths2
PrimaryNumber of Participants With Serious Adverse Events Reported During the Open-Label Period

SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

Time frame:
Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
Reported as:
Number · participants
Number of Participants With Serious Adverse Events Reported During the Open-Label Period
participantsABA + MTX (Open Label)
Any SAE29
Infections and infestations8
Gastrointestinal disorders4
Nervous system disorders4
Cardiac disorders3
Hepatobiliary disorders3
Eye disorders2
Musculoskeletal and connective tissue disorders2
Vascular disorders2
Immune System Disorders1
Injury, Poisoning, and Procedural Complications1
Investigations1
Metabolism and Nutrition Disorders1
Renal and Urinary Disorders1
Respiratory, Thoracic, and Mediastinal Disorders1
SecondaryNumber of Participants With Anti-abatacept or Anti-CTLA4-T Responses During the Open-Label Period (From Month 12 to Month 24) as Analyzed by ELISA

Serum samples were analyzed by ELISA to detect antibodies against the whole molecule (both CTLA4 and Ig \[anti-abatacept antibody\]) or solely to CTLA4 (anti-CTLA4-T antibody). Reported as titer, the reciprocal of the sample dilution which yielded a signal equivalent to the statistically set cut point for the assay. For the anti-abatacept assay, minimum required dilution is 400-fold, therefore seronegative samples are those \< lowest reportable titer (\<400). For the anti-CTLA4-T assay, minimum required dilution is 25-fold, therefore seronegative samples are those \< lowest reportable titer (\<25).

Time frame:
Includes open-label data up to approximately 85 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
Reported as:
Number · participants
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses During the Open-Label Period (From Month 12 to Month 24) as Analyzed by ELISA
participantsAnti-Abatacept Antibody ResponseAnti-CTLA4-T Antibody Response
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses During the Open-Label Period (From Month 12 to Month 24) as Analyzed by ELISA1316
SecondaryNumber of Participants With Health Assessment Questionnaire (HAQ) Response at Month 24

Physical function was evaluated using the HAQ-disability index (HAQ-DI), a questionnaire with 20 questions assessing function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; 3 = unable to do. The 8 category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). Higher scores indicate greater dysfunction. HAQ response=improvement of at least 0.3 units from baseline.

Time frame:
Baseline, Month 24
Reported as:
Number · participants
Number of Participants With Health Assessment Questionnaire (HAQ) Response at Month 24
participantsABA + MTX (Double-Blind)PLA + MTX (Double-Blind)
Number of Participants With Health Assessment Questionnaire (HAQ) Response at Month 24189178
SecondaryMean Change From Baseline in Radiographic Total, Erosion and JSN Scores to Month 24

To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. Change from baseline = Postbaseline - baseline value.

Time frame:
Baseline, Month 24
Reported as:
Mean · units on a scale
Mean Change From Baseline in Radiographic Total, Erosion and JSN Scores to Month 24
units on a scaleABA + MTX (Double-Blind)PLA + MTX (Double-Blind)
Erosion Score Baseline Mean5.91 ± 6.485.49 ± 5.85
Erosion Score Mean Change from Baseline0.59 ± 2.311.40 ± 3.08
JSN Score Baseline Mean1.83 ± 3.821.75 ± 3.92
JSN Score Mean Change from Baseline0.25 ± 1.030.34 ± 0.99
Total Score Baseline Mean7.73 ± 9.507.24 ± 8.89
Total Score Mean Change from Baseline0.84 ± 3.221.75 ± 3.59
PrimaryNumber of Participants With SAEs With an Outcome of Death During the Open-label Period

Any untoward medical occurrence (SAE) that resulted in death

Time frame:
Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
Reported as:
Number · participants
Number of Participants With SAEs With an Outcome of Death During the Open-label Period
participantsABA + MTX (Open-Label)
Pneumonia1
Pneumonia/septic shock1
PrimaryIncidence Rates of Autoimmune Disorders in ABA-Treated Participants

The incidence rates of autoimmune disorders are defined as the (number of patients experiencing the event/exposure within the period)\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.

Time frame:
Double Blind Period (+56 days post last dose in double-blind period or start of open-label period, whichever came first). Open-label period (56 days post last dose in the open-label period or start of maintenance sub-study, whichever came first).
Reported as:
Number · Number of participants/100 patient-years
Incidence Rates of Autoimmune Disorders in ABA-Treated Participants
Number of participants/100 patient-yearsABA + MTX (Double-Blind)ABA + MTX (Open-Label)
Incidence Rates of Autoimmune Disorders in ABA-Treated Participants2.471.30
PrimaryIncidence Rates of Infections and Infestations of Adverse Events in ABA-Treated Participants

The incidence rates of infections and infestations are defined as the (number of patients experiencing the event /exposure within the period)\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.

Time frame:
Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first).
Reported as:
Number · Number of patients/100 patient-years
Incidence Rates of Infections and Infestations of Adverse Events in ABA-Treated Participants
Number of patients/100 patient-yearsABA + MTX (Double-Blind)ABA + MTX (Open-Label)
Incidence Rates of Infections and Infestations of Adverse Events in ABA-Treated Participants78.3766.68
PrimaryIncidence Rates of Malignant Neoplasm Adverse Events in ABA-Treated Participants

The incidence rates of malignant neoplasms are defined as the (number of patients experiencing the event /exposure within the period)\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.

Time frame:
Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first).
Reported as:
Number · number of patients/100 patient-years
Incidence Rates of Malignant Neoplasm Adverse Events in ABA-Treated Participants
number of patients/100 patient-yearsABA + MTX (Double-Blind)ABA + MTX (Open-Label)
Incidence Rates of Malignant Neoplasm Adverse Events in ABA-Treated Participants0.810
PrimaryNumber of Participants With a Serious Acute-Infusional AE of Anaphylactic Shock During Open-Label Period

There were 107 Prespecified, acute-infusional SAEs (occurring within 1 hour after the start of study drug infusion) pre-specified in the protocol; anaphylactic shock was the only one occuring in this study.

Time frame:
Open-Label Period (Month 12 to Month 24)
Reported as:
Number · Participants
Number of Participants With a Serious Acute-Infusional AE of Anaphylactic Shock During Open-Label Period
ParticipantsABA + MTX (Open-label)
Number of Participants With a Serious Acute-Infusional AE of Anaphylactic Shock During Open-Label Period1
PrimaryNumber of Participants With Select Blood Chemistry Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period

Number of subjects with high liver function and kinedy tests: alkaline phosphatase (ALP) \>2x upper limit of normal (ULN) or if pretreatment (PRE-RX) \>ULN then \>3x PRE-RX; aspartate aminotransferase (AST) \>3x ULN or if PRE-RX \>ULN then \>4x PRE-RX; alanine aminotransferase (ALT) \>3x ULN or if PRE-RX \>ULN then \>4x PRE-RX; g-glutamyl transferase (GGT)\>2x ULN or if PRE-RX \>ULN then \>3x PRE-RX; total bilirubin \>2x ULN or if PRE-RX \>ULN then \>4x PRE-RX; blood urea nitrogen \>2x PRE-RX; creatinine \>1.5x PRE-RX.

Time frame:
Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
Reported as:
Number · participants
Number of Participants With Select Blood Chemistry Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period
participantsABA + MTX (Open-Label)
ALP (n=459)2
AST (n=459)10
ALT (n=459)24
GGT (n=459)15
Total Bilirubin (n=459)0
Blood Urea Nitrogen (n=459)13
Creatinine (n=457)81
PrimaryNumber of Participants With Hematology Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period

Marked abnormalities in hemoglobin \>3 g/dL decrease from PRE-RX; hematocrit \<0.75x PRE-RX; erythrocytes \<0.75x PRE-RX; platelet count \<0.67x lower limit of normal (LLN) or \>1.5x ULN or if PRE-RX \<LLN then \<0.5x PRE-RX and \<100,000/mm3; leukocytes \<0.75x LLN or \>1.25x ULN or if PRE-RX \<LLN then \<0.8x PRE-RX or \>ULN if PRE-RX \>ULN then \>1.2x PRE-RX or \<LLN; neutrophils if value \<1.00 x10\^3 c/uL; lymphocytes if value \<.750 x10\^3 c/uL or if value \>7.50 x10\^3 c/uL; monocytes if value \>2000/MM3; basophils if value \>400/mm3; eosinophils if value \>.750 x10\^3 c/uL

Time frame:
Continuously from start of open-label period up to 56 days post the last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
Reported as:
Number · participants
Number of Participants With Hematology Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period
participantsABA + MTX (Open-Label)
Low Hemoglobin (n=458)9
Low Hematocrit (n=458)5
Low Erythrocyte (n=458)8
Low Platelet Count (n=455)1
High Platelet Count (n=455)1
Low Leukocytes (n=458)14
High Leukocytes (n=458)12
Low Neutrophils + Bands (absolute) (n=459)6
Low Lymphocytes (absolute) (n=459)39
High Lymphocytes (absolute) (n=459)1
High Monocytes (absolute) (n=459)0
High Basophils (absolute) (n=459)2
High Eosinophils (absolute) (n=459)19
SecondaryNumber of Participants Without Radiographic Progression (as Measured by in Erosion Scores, JSN Scores, and Total Scores) From Baseline at Month 24

Participants with no radiographic progression (defined as change in score \<=0 or \<=0.5), from baseline to Month 24. To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.

Time frame:
Baseline, Month 24
Reported as:
Number · Participants
Number of Participants Without Radiographic Progression (as Measured by in Erosion Scores, JSN Scores, and Total Scores) From Baseline at Month 24
ParticipantsABA + MTX (Double-Blind)PLA + MTX (Double-Blind)
Change from Baseline <= 0 in Erosion Score12592
Change from Baseline <= 0.5 in Erosion Score144114
Change from Baseline <= 0 in JSN Score175150
Change from Baseline <= 0.5 in JSN Score190166
Change from Baseline <= 0 in Total Score12184
Change from Baseline <= 0.5 in Total Score139107
SecondaryNumber of Participants Without Radiographic Progression (as Measured by in Erosion Scores, JSN Scores, and Total Scores) at Month 24 in Participants Without Progression at Month 12

Participants with no radiographic progression ((defined as change in score \<=0 or \<=0.5), sustained from Month 12 and Month 24. To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.

Time frame:
Month 12, Month 24
Reported as:
Number · Participants
Number of Participants Without Radiographic Progression (as Measured by in Erosion Scores, JSN Scores, and Total Scores) at Month 24 in Participants Without Progression at Month 12
ParticipantsABA + MTX (Double-Blind)PLA + MTX (Double-Blind)
Erosion Score Sustained <=0 (n=125; n=100)11687
Erosion Score Sustained <=0.5 (n=145; n=114)135107
JSN Score Sustained <=0 (n=180; n=165)169150
JSN Score Sustained <=0.5 (n=192; n=177)185163
Total Score sustained <=0 (n=123; n=97)11281
Total Score sustained <=0.5 (n=144; n=112)131101
SecondaryMean Difference Observed in Change From Baseline to Month 12 and Between Month 12 and Month 24 in Radiographic Scores (Total Score)

Mean difference observed in change from baseline to Month 12 and between Month 12 and Month 24 in radiographic scores (Total Score). To assess joint damage, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Mean · units on a scale
Mean Difference Observed in Change From Baseline to Month 12 and Between Month 12 and Month 24 in Radiographic Scores (Total Score)
units on a scaleYear 1 ChangeYear 2 Change
Mean Difference Observed in Change From Baseline to Month 12 and Between Month 12 and Month 24 in Radiographic Scores (Total Score)0.66 ± 0.130.18 ± 0.13
Statistical analysis
  • Year 1 Change vs Year 2 Change · signed rank test · p = <0.001
SecondaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Reported During the Double-blind Period

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

Time frame:
Includes data up to 56 days post the last dose in the double-blind period or start of the open-label period, whichever occurred first.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Reported During the Double-blind Period
participantsABA + MTX (Double-Blind)PLA + MTX (Double-Blind)
Deaths24
SAEs2020
Related SAEs56
Discontinued due to SAEs33
AEs217211
Related AEs98114
Discontinued due to AEs811
SecondaryNumber of Participants With Laboratory Values Meeting the Marked Abnormality Criteria During the Double-blind Period

Number of participants with laboratory values (hematology, liver and kidney functions, electrolytes, glucose tests, protein tests, metabolite tests, and urine chemistry tests) considered markedly abnormal according to prespecified protocol criteria

Time frame:
Includes data up to 56 days post the last dose in the double-blind period or start of the open-label period, whichever occurred first.
Reported as:
Number · participants
Number of Participants With Laboratory Values Meeting the Marked Abnormality Criteria During the Double-blind Period
participantsABA + MTX (Double-Blind)PLA + MTX (Double-Blind)
Low Hemoglobin (n=254; n=251)33
Low Hematocrit (n=254; n=250)12
Low Erythrocytes (n=254; n=250)14
Low Platelet Count (n=252; n=250)01
High Platelet Count (n=252; n=250)13
Low Leukocytes (n=254; n=251)511
High Leukocytes (n=254; n=251)514
Low Neutrophils + Bands (absolute) (n=254; n=252)25
Low Lymphocytes (absolute) (n=254; n=252)1329
High Lymphocytes (absolute) (n=254; n=252)00
High Monocytes (absolute) (n=254; n=252)11
High Basophils (absolute) (n=254; n=252)00
High Eosinophils (absolute) (n=254; n=252)713
High Alkaline Phosphatase (n=254; n=253)10
High Aspartate Aminotransferase (n=254; n=253)714
High Alanine Aminotransferase (n=254; n=253)1521
G-Glutamyl Transferase (n=254; n=253)119
High Bilirubin, Total (n=254; n=253)02
High Blood Urea Nitrogen (n=254; n=253)910
High Creatinine (n=254; n=251)3332
Low Sodium, Serum (n=254; n=253)01
High Sodium, Serum (n=254; n=253)20
Low Potassium, Serum (n=254; n=251)63
High Potassium, Serum (n=254; n=251)32
Low Chloride, Serum (n=254; n=253)00
High Chloride, Serum (n=254; n=253)10
Low Calcium, Total (n=254; n=253)00
High Calcium, Total (n=254; n=253)00
Low Phosphorus, Inorganic (n=254; n=251)12
High Phosphorus, Inorganic (n=254; n=251)33
Low Glucose, Serum (n=254; n=253)2224
High Glucose, Serum (n=254; n=253)1013
Low Protein, Total (n=254; n=253)20
High Protein, Total (n=254; n=253)01
Low Albumin (n=254; n=253)25
High Protein, Urine (n=252; n=250)63
High Glucose, Urine (n=252; n=250)46
High Blood, Urine (n=252; n=250)3022
High Leukocyte Esterase (n=87; n=88)1313
High Red Blood Cells, Urine (n=92; n=103)3025
High White Blood Cells, Urine (n=94; n=105)3842
High Uric Acid (n=254; n=253)11

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept—20/256 (7.8%)150/256 (58.6%)
Placebo—20/253 (7.9%)155/253 (61.3%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventAbataceptPlacebo
PNEUMONIAInfections and infestations1/2563/253
DEPRESSIONPsychiatric disorders2/2560/253
MYOCARDIAL INFARCTIONCardiac disorders1/2561/253
CARDIAC FAILURE CONGESTIVECardiac disorders0/2561/253
CHOLECYSTITISHepatobiliary disorders0/2561/253
ACUTE HEPATIC FAILUREHepatobiliary disorders0/2561/253
ANAPHYLACTIC REACTIONImmune system disorders0/2561/253
INTRACRANIAL PRESSURE INCREASEDNervous system disorders0/2561/253
ABDOMINAL PAINGastrointestinal disorders0/2561/253
GASTROENTERITISInfections and infestations1/2561/253
Most frequent other events
Showing 10 of 15
Most frequent other events
EventAbataceptPlacebo
NAUSEAGastrointestinal disorders26/25641/253
HEADACHENervous system disorders30/25623/253
NASOPHARYNGITISInfections and infestations21/25626/253
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations26/25626/253
DIARRHOEAGastrointestinal disorders17/25624/253
INFLUENZAInfections and infestations19/25623/253
URINARY TRACT INFECTIONInfections and infestations17/25622/253
COUGHRespiratory, thoracic and mediastinal disorders21/25616/253
DIZZINESSNervous system disorders19/25613/253
BRONCHITISInfections and infestations18/25612/253

Baseline characteristics

Age Continuous
Age Continuous(years)ABA + MTX (Double-Blind)PLA + MTX (Double-Blind)Total
Mean50.1 ± 12.449.7 ± 13.049.9 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)ABA + MTX (Double-Blind)PLA + MTX (Double-Blind)Total
Female196199395
Male6054114
Anti-Cyclic Citrullinated Peptide 2 (CCP2) Status
Anti-Cyclic Citrullinated Peptide 2 (CCP2) Status(participants)ABA + MTX (Double-Blind)PLA + MTX (Double-Blind)Total
unknown202
positive236217453
negative183654
Duration of Rheumatoid Arthritis (RA) Disease
Duration of Rheumatoid Arthritis (RA) Disease(participants)ABA + MTX (Double-Blind)PLA + MTX (Double-Blind)Total
</= 6 months167157324
> 6 months - 12 months363470
> 12 months5362115
Rheumatoid Factor (RF) Status
Rheumatoid Factor (RF) Status(participants)ABA + MTX (Double-Blind)PLA + MTX (Double-Blind)Total
unknown112
positive246245491
negative9716
Disease Activity Scale 28 (DAS 28) C-reactive Protein (CRP)
Disease Activity Scale 28 (DAS 28) C-reactive Protein (CRP)(units on a scale)ABA + MTX (Double-Blind)PLA + MTX (Double-Blind)Total
Mean6.3 ± 1.06.2 ± 1.06.3 ± 1.0
Duration of RA
Duration of RA(months)ABA + MTX (Double-Blind)PLA + MTX (Double-Blind)Total
Mean6.2 ± 7.56.7 ± 7.16.5 ± 7.3
Erosion Score
Erosion Score(units on a scale)ABA + MTX (Double-Blind)PLA + MTX (Double-Blind)Total
Mean5.4 ± 6.14.8 ± 5.45.1 ± 5.8

8 further baseline measures are reported on the registry.

08

Study locations

89 sites
  • Rheumatology Associates Of North Alabama
    Huntsville, Alabama 35801, United States
  • Talbert Medical Group
    Huntington Beach, California 92646, United States
  • Arthritis Assoc And Osteo Ctr Of Col Sprgs
    Colorado Springs, Colorado 80910, United States
  • New England Research Associates, Llc
    Trumbull, Connecticut 06611, United States
  • Diagnostic Rheumatology And Research
    Indianapolis, Indiana 46227, United States
  • Osteoporosis And Clinical Trials Center
    Cumberland, Maryland 21502, United States
  • Malamet & Klein, Md, Pa
    Hagerstown, Maryland 21740, United States
  • Arthritis Center Of Nebraska
    Lincoln, Nebraska 68516, United States
  • Regional Rheumatology Associates
    Binghamton, New York 13905, United States
  • Carolina Bone & Joint
    Charlotte, North Carolina 28210, United States
  • Physicians East, Pa
    Greenville, North Carolina 27834, United States
  • Carolina Pharmaceutical Research
    Statesville, North Carolina 28625, United States
  • Lion Research
    Norman, Oklahoma 73071, United States
  • Health Research Of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • Lynn Health Sciences Institute
    Oklahoma City, Oklahoma 73112, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Low Country Research Center
    Charleston, South Carolina 29406, United States
  • Walter F Chase Md Pa
    Austin, Texas 78705, United States
  • Arthritis Clinic Of Northern Virginia, P.C.
    Arlington, Virginia 22205, United States
  • Local Institution
    Malvern, Victoria 3144, Australia
  • Local Institution
    Shenton Park, Western Australia 6008, Australia
  • Local Institution
    Antwerpen, 2020, Belgium
  • Local Institution
    Bruxelles, 1070, Belgium
  • Local Institution
    Bruxelles, 1200, Belgium
  • Local Institution
    Hasselt, 3500, Belgium
  • Local Institution
    Leuven, 3000, Belgium
  • Local Institution
    Goiania, Goias 74043, Brazil
  • Local Institution
    Curitiba, Parana 80060, Brazil
  • Local Institution
    Rio De Janeiro - Rj, Rio De Janeiro 20551, Brazil
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 91610, Brazil
  • Local Institution
    Sao Paulo, 04039, Brazil
  • Local Institution
    Sao Paulo, 04230, Brazil
  • Local Institution
    St. John'S, Newfoundland and Labrador A1B 3E1, Canada
  • Local Institution
    Kitchener, Ontario N2M 5N6, Canada
  • Local Institution
    Toronto, Ontario M5G 1X5, Canada
  • Local Institution
    Montreal, Quebec H2L 1S6, Canada
  • Local Institution
    Sherbrooke, Quebec J1H 5N4, Canada
  • Local Institution
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Local Institution
    Quebec, G1V 3M7, Canada
  • Local Institution
    Prague 2, 128 50, Czech Republic
  • Local Institution
    Dijon, 21000, France
  • Local Institution
    Montpellier Cedex 5, 34295, France
  • Local Institution
    Nice Cedex 03, 06202, France
  • Local Institution
    Strasbourg Cedex, 67098, France
  • Local Institution
    Berlin, 14059, Germany
  • Local Institution
    Hamburg, 22081, Germany
  • Local Institution
    Leipzig, 04103, Germany
  • Local Institution
    Leipzig, 04229, Germany
  • Local Institution
    Jesi(Ancona), 60055, Italy
  • Local Institution
    Milano, 20157, Italy
  • Local Institution
    Anyang, 431-070, Korea, Republic of
  • Local Institution
    Daegu, 705-718, Korea, Republic of
  • Local Institution
    Daejeon, 302-799, Korea, Republic of
  • Local Institution
    Seoul, 110-744, Korea, Republic of
  • Local Institution
    Seoul, 133-792, Korea, Republic of
  • Local Institution
    Seoul, 137-040, Korea, Republic of
  • Local Institution
    Seoul, 138-736, Korea, Republic of
  • Local Institution
    D.f., Distrito Federal 06700, Mexico
  • Local Institution
    Metepec, Estado De Mexico 52140, Mexico
  • Local Institution
    Leon, Guanajuato 37000, Mexico
  • Local Institution
    Guadalajara, Jalisco 42650, Mexico
  • Local Institution
    Guadalajara, Jalisco 44340, Mexico
  • Local Institution
    Guadalajara, Jalisco 44690, Mexico
  • Local Institution
    Morelia, Michioacan 58000, Mexico
  • Local Institution
    Cuernavaca, Morelos 62270, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64020, Mexico
  • Local Institution
    Chihuahua, 31000, Mexico
  • Local Institution
    San Luis Potosi, 78240, Mexico
  • Local Institution
    Amsterdam, 1081 HV, Netherlands
  • Local Institution
    Leiden, 2300 RC, Netherlands
  • Local Institution
    Nijmegen, 6500 HB, Netherlands
  • Local Institution
    Poznan, 60773, Poland
  • Local Institution
    Poznan, 61-545, Poland
  • Local Institution
    Warszawa, 02-637, Poland
  • Local Institution
    Ponce, 00716, Puerto Rico
  • Local Institution
    Moscow, 115522, Russian Federation
  • Local Institution
    Moscow, 119049, Russian Federation
  • Local Institution
    Bloemfontein, Free State 9317, South Africa
  • Local Institution
    Muckleneuk, Gauteng 0002, South Africa
  • Local Institution
    Pretoria, Gauteng 0084, South Africa
  • Local Institution
    Berea, Kwa Zulu Natal 4001, South Africa
  • Local Institution
    Panorama, Western Cape 7506, South Africa
  • Local Institution
    A Coruna, 15706, Spain
  • Local Institution
    Santander, 39008, Spain
  • Local Institution
    Sevilla, 41071, Spain
  • Local Institution
    Manchester, Greater Manchester M13 9WL, United Kingdom
  • Local Institution
    Glasgow, Lanarkshire G12 0YN, United Kingdom
  • Local Institution
    Leeds, North Yorkshire LS7 4SA, United Kingdom
  • Local Institution
    Newcastle, Northumberland NE1 4LP, United Kingdom
09

References and documents

Publications

  • Durez P, Westhovens R, Baeke F, Elbez Y, Robert S, Ahmad HA. Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study. BMC Rheumatol. 2022 Apr 14;6(1):24. doi: 10.1186/s41927-022-00252-4. PubMed 35418172 ↗
  • Jansen DTSL, Emery P, Smolen JS, Westhovens R, Le Bars M, Connolly SE, Ye J, Toes REM, Huizinga TWJ. Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. RMD Open. 2018 Mar 30;4(1):e000564. doi: 10.1136/rmdopen-2017-000564. eCollection 2018. PubMed 29657830 ↗
  • Smolen JS, Wollenhaupt J, Gomez-Reino JJ, Grassi W, Gaillez C, Poncet C, Le Bars M, Westhovens R. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). Arthritis Res Ther. 2015 Jun 11;17(1):157. doi: 10.1186/s13075-015-0671-9. PubMed 26063454 ↗
  • Bathon J, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH, Genant H, Peterfy C, Becker JC, Covucci A, Moniz Reed D, Helfrick R, Westhovens R. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis. 2011 Nov;70(11):1949-56. doi: 10.1136/ard.2010.145268. Epub 2011 Aug 6. PubMed 21821865 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Feb 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2005
First posted
Jul 22, 2005
Start
Jul 2005
Primary completionActual
Feb 2008
CompletionActual
Feb 2009
Results first posted
Jul 13, 2010
Last update
Nov 16, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00122382
First posted
Jul 22, 2005
Start date
Jul 2005
Primary completion
Feb 2008
Completion
Feb 2009
Results posted
Jul 13, 2010
Last update
Nov 16, 2010

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abatacept · Methotrexate

Start the discussion